Summary
Biogen Inc. (BIIB) filed an 8-K on April 9, 2021, primarily announcing changes to its Board of Directors related to the upcoming 2021 annual meeting of stockholders. Robert W. Pangia will retire and not seek reelection, a decision stated to be amicable and not due to any disagreements. Concurrently, Biogen announced the nomination of two new individuals, Maria C. Freire, Ph.D. and William D. Jones, to join the Board.
Key Highlights
- 1Director Robert W. Pangia to retire and not stand for reelection at the June 2, 2021 annual meeting.
- 2Mr. Pangia's retirement is not due to any disagreement with the Company's operations, policies, or practices.
- 3Nomination of Maria C. Freire, Ph.D. and William D. Jones for election to the Board of Directors.
- 4These changes are in anticipation of the Company's 2021 annual meeting of stockholders.
- 5Biogen is encouraging stockholders to read its forthcoming proxy statement for important details regarding the annual meeting and director nominations.
Frequently Asked Questions
Robert W. Pangia, a director, is retiring and will not stand for reelection at the upcoming 2021 annual meeting of stockholders. His departure is amicable and does not stem from any disputes with the company.
Biogen has nominated Maria C. Freire, Ph.D. and William D. Jones to stand for election to the Board of Directors at the 2021 annual meeting.
Mr. Pangia will remain a director until the annual meeting of stockholders scheduled for June 2, 2021. The election of the new directors will occur at this same meeting.
Biogen intends to file a proxy statement with the SEC that will contain important information regarding the matters to be considered at the 2021 annual meeting. Investors are strongly encouraged to read this proxy statement when it becomes available on Biogen's website or the SEC's website.